与侵袭性前列腺癌相关的非洲血统功能获得性HOXB13变异体的临床与功能分析
研究基于2019至2022年21393例接受基因检测的前列腺癌男性真实数据,比较HOXB13(X285K)与HOXB13(G84E)及BRCA2致病/可能致病变异的临床相关性,并通过体外细胞系模型阐明X285K的致癌机制。X285K在自我报告黑人患者中显著富集,携带者具有与BRCA2携带者相似的侵袭性前列腺癌特征,功能研究揭示X285K通过增强与E2F/MYC特征相关基因启动子/增强子结合发挥功能获得性致癌作用。
要点
- HOXB13(X285K)在自我报告黑人患者中显著富集(1.01% vs 白人0.01%)。
- X285K和BRCA2致病/可能致病变异携带者较G84E携带者呈现更侵袭性疾病趋势。
- X285K蛋白通过增强结合E2F/MYC特征基因启动子/增强子发挥功能获得性致癌机制。
核心结论
- HOXB13(X285K)在自我报告黑人患者中显著富集,真实临床环境中检测到的X285K携带者具有与BRCA2携带者相似的侵袭性前列腺癌特征。
- 功能研究揭示X285K蛋白在调控E2F/MYC特征方面具有独特的功能获得性致癌机制。
- 作者认为X285K变异在临床和功能上与侵袭性前列腺癌相关,支持在黑人男性中进行X285K基因检测并对该变异携带者进行早期疾病筛查。
研究设计与样本
- 研究收集2019至2022年21393例接受基因检测的前列腺癌男性的真实世界数据,并按自我报告的种族/民族、Gleason评分和美国癌症联合委员会分期使用精确检验比较各组基因检测结果。
- 建立体外细胞系模型,通过RNA测序、染色质免疫沉淀测序和Western blot分析评估X285K蛋白的致癌功能。
主要发现
- HOXB13(X285K)在自我报告黑人患者中显著富集(1.01%) versus 白人患者(0.01%)。
- 观察到HOXB13(X285K)和BRCA2致病/可能致病变异携带者较HOXB13(G84E)携带者呈现更侵袭性疾病的趋势。
- 将野生型HOXB13蛋白替换为X285K蛋白导致E2F/MYC特征的功能获得,经细胞周期蛋白B1和c-Myc表达升高验证,而未影响雄激素反应特征。
- 细胞周期蛋白B1和c-Myc表达升高可由X285K蛋白与这些基因的启动子和增强子结合增强来解释。
临床怎么用
- 作者认为X285K变异在临床和功能上与侵袭性前列腺癌相关,支持在黑人男性中进行X285K基因检测并对该变异携带者进行早期疾病筛查。
局限性
- 研究缺乏所有受试患者的完整临床结局数据。
- 功能分析中使用了单一细胞系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent reports have uncovered a HOXB13 variant (X285K) predisposing to prostate cancer in men of West African ancestry. The clinical relevance and protein function associated with this inherited variant are unknown. OBJECTIVE: To determine the clinical relevance of HOXB13 (X285K) in comparison with HOXB13 (G84E) and BRCA2 pathogenic/likely pathogenic (P/LP) variants, and to elucidate the oncogenic mechanisms of the X285K protein. DESIGN, SETTING, AND PARTICIPANTS: Real-world data were collected from 21,393 men with prostate cancer undergoing genetic testing from 2019 to 2022, and in vitro cell-line models were established for the evaluation of oncogenic functions associated with the X285K protein. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Genetic testing results were compared among patient groups according to self-reported race/ethnicity, Gleason scores, and American Joint Committee on Cancer stages using the exact test. Oncogenic functions of X285K were evaluated by RNA sequencing, chromatin immunoprecipitation sequencing, and Western blot analyses. RESULTS AND LIMITATIONS: HOXB13 (X285K) was significantly enriched in self-reported Black (1.01%) versus White (0.01%) patients. We observed a trend of more aggressive disease in the HOXB13 (X285K) and BRCA2 P/LP carriers than in the HOXB13 (G84E) carriers. Replacement of the wild-type HOXB13 protein with the X285K protein resulted in a gain of an E2F/MYC signature, validated by the elevated expression of cyclin B1 and c-Myc, without affecting the androgen response signature. Elevated expression of cyclin B1 and c-Myc was explained by enhanced binding of the X285K protein to the promoters and enhancers of these genes. The limitations of the study are the lack of complete clinical outcome data for all patients studied and the use of a single cell line in the functional analysis. CONCLUSIONS: HOXB13 (X285K) is significantly enriched in self-reported Black patients, and X285K carriers detected in the real-world clinical setting have aggressive prostate cancer features similar to the BRCA2 carriers. Functional studies revealed a unique gain-of-function oncogenic mechanism of X285K protein in regulating E2F/MYC signatures. PATIENT SUMMARY: The HOXB13 (X285K) variant is clinically and functionally linked to aggressive prostate cancer, supporting genetic testing for X285K in Black men and early disease screening of carriers of this variant.
引用
- Kanayama M, Chen Y, Rabizadeh D, et al. Clinical and Functional Analyses of an African-ancestry Gain-of-function HOXB13 Variant Implicated in Aggressive Prostate Cancer. Eur Urol Oncol. 2023. PMID: 37806842. doi:10.1016/j.euo.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。